AsiaNet  90204

DONGGUAN, China, June 21, 2021 /PRNewswire=KYODO JBN/ --

Mucormycosis or black fungus, a devastating infection that soars in India

during COVID-19 has seized global attention. Recently, the country's

mucormycosis cases reached over 57,150 and resulted in 54% mortality (

https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html#:~:text=Mucormycosis%20is%20frequently%20a%20life,cause%20mortality%20rate%20of%2054%25

). Apart from the association with high diabetes prevalence in India, COVID-19

infected countries (Pakistan, Russia, Nepal(

https://timesofindia.indiatimes.com/world/south-asia/2-dead-and-11-suffering-from-black-fungus-in-nepal/articleshow/83334621.cms

), Chile(

https://www.thesun.co.uk/news/15151118/fears-black-fungus-indian-variant-found-outside-india/?utm_campaign=native_share&utm_source=sharebar_native&utm_medium=sharebar_native

), Brazil, etc.) have also described the same issue, areas with high diabetes

and COVID-19 infection rates should be alarmed.

Unfortunately, mucormycosis is always being diagnosed late with prolonged

COVID-19 healthcare burdens that deteriorate the situation. As a company making

continuous research and contribution to the world's major infectious diseases

with the mission to Enable Disease Identification Earlier, More Accurate,

Convenient and Affordable, Fapon Biotech Inc.(

http://en.faponbiotech.com/index.html ) (Fapon Biotech) calls for cooperation

with academic and industry partners in developing mucormycosis diagnostic tests

to ease the challenge by sharing the abilities of upstream raw material

development platforms and downstream reagent application platforms.

Fapon Biotech is one of the mainstream COVID-19 reagent raw material suppliers

with proven experiences helping partners to launch accredited COVID-19 reagents

in a short time. The company has over 1000 IVD partners worldwide with more

than 10 years of business operation in India. Its technology platforms can

match the R&D process from partners easily and provide supports from biomarker

discovery to commercialization. Through different application platforms of

Fapon Biotech (Colloidal Gold/Immunofluorescence/ELISA/CLIA/Latex-Enhanced

Immunoturbidimetry/PCR/etc.), biomarkers can quickly complete the process of

application development. For partners encountering production challenges, OEM

and contract manufacturing services with the capacity reaching hundreds of

grams of each batch are available. Because of a strong relationship with

laboratories and IVD manufacturers in India, cooperating with Fapon Biotech

will have the access to more resources and commercial opportunities, such as

clinical samples for research and product validation, technology iterations,

product launch and promotion, etc.

As the virus continues its mutation and triggers diseases like mucormycosis to

complicate the situation, rapid responses via global cooperation will be

crucial for areas with overwhelmed healthcare burdens. Fapon Biotech is

committed to fueling the advancement of COVID-19 diagnosis through

collaborations with international IVD partners.

About Fapon Biotech

Fapon Biotech was founded in 2001. Guided by the mission of "Enable Disease

Identification Earlier, More Accurate, Convenient and Affordable," the company

focuses on the future needs of biotechnology developments and provides global

diagnostic companies with high-performance IVD reagent raw materials, such as

antigens, antibodies, and enzymes, as well as one-stop solutions with

instrument and reagent services.

SOURCE:  Fapon Biotech Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=394248

   Caption: Fapon Biotech calls for cooperation with academic and industry partners in

developing mucormycosis diagnostic tests to ease the challenge by sharing the

abilities of upstream raw material development platforms and downstream reagent

application platforms.